Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) disclosed a small-scale share buyback executed on 30 June 2026. Key details are as follows:
• Transaction overview: The company repurchased 100,000 H shares on the Hong Kong Stock Exchange at prices between HKD 3.15 and HKD 3.17 per share, translating to a volume-weighted average of HKD 3.162 and an aggregate outlay of HKD 0.32 million.
• Impact on share capital: The buyback trimmed WEIGAO GROUP’s issued share base (excluding treasury shares) by 0.0022% to 4,462.27 million shares. Treasury share holdings rose to 60.06 million, while the total issued share count remained unchanged at 4,522.33 million.
• Repurchase mandate utilisation: The transaction forms part of the mandate authorised by shareholders on 29 May 2026, which permits the repurchase of up to 446.46 million shares. Including this latest purchase, cumulative buybacks under the mandate have reached 2.74 million shares—equivalent to 0.61% of the share count on the mandate date—leaving roughly 443.73 million shares (about 99.4% of the authorised limit) still available for potential future repurchases.
• Post-repurchase restrictions: In accordance with Hong Kong listing rules, WEIGAO GROUP is subject to a moratorium on new share issues or sales of treasury shares until 30 July 2026.
The board confirmed that the repurchases complied with all applicable regulations and that all conditions related to the buyback mandate were satisfied.
Comments